Search

Your search keyword '"Bone Density Conservation Agents economics"' showing total 298 results

Search Constraints

Start Over You searched for: Descriptor "Bone Density Conservation Agents economics" Remove constraint Descriptor: "Bone Density Conservation Agents economics"
298 results on '"Bone Density Conservation Agents economics"'

Search Results

1. Cost-effectiveness of a multicomponent-adherence intervention in fracture liaison services.

2. The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.

3. [Cost-effectiveness analysis of fracture liaison services in Catalonia].

4. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium.

5. Societal costs before and up to 1 year after the first fracture liaison service visit in patients requiring anti-osteoporosis treatments.

6. Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.

7. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.

8. Assessing the effects of National Health Insurance reimbursement policy revisions for anti-osteoporotic drugs in Korean women aged 50 or older.

9. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.

10. Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis.

11. Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective.

12. Cost-effectiveness analyses of interventions to improve osteoporosis care in France.

13. Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data.

14. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

15. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.

16. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.

17. Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.

18. Hip Fractures in Older Adults in 2019.

19. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.

20. Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China.

21. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.

22. Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases.

23. Abaloparatide (Tymlos) for Osteoporosis.

24. Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS.

25. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.

26. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.

27. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.

28. Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients.

29. Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA.

30. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.

31. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.

32. Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464).

33. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.

34. Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.

35. Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review.

36. A health economic simulation model for the clinical management of osteoporosis.

37. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.

38. Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis.

39. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).

40. Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004-2015.

41. Adherence to osteoporosis medicines in Estonia-a comprehensive 15-year retrospective prescriptions database study.

42. Cost-effective osteoporosis treatment thresholds for people living with HIV infection in Greece.

43. A comparative study between the implementation of the FRIDEX calibration and the NOGG guideline in the management of osteoporosis in routine clinical practice.

44. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.

45. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.

46. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.

47. Economic Consequences and Potentially Preventable Costs Related to Osteoporosis in the Netherlands.

48. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.

49. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.

50. Treatment of postmenopausal osteoporosis: a literature-based algorithm for use in the public health care system.

Catalog

Books, media, physical & digital resources